Author

Grace Segall

Observed names: G. Segall, Segall, Grace

Institution: Eli Lilly (United States)

Observed institution: Eli Lilly (United States)

ORCID: 0000-0002-4942-7633

Observed ORCID: 0000-0002-4942-7633

OpenAlex ID: A5000647770

Treatment patterns and outcomes in advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in China

2025 · Jingdong Zhang, Guangyu Wang, et al. · Future Oncology · 5

Diagnosis, Treatment Patterns, and Outcomes in Real-World Patients with RET Fusion-Positive Non-small Cell Lung Cancer in China

2024 · Shun Lu, Lan Shen, et al. · Advances in Therapy · 5

Real-world clinical profile, RET mutation testing, treatments and patient-related outcomes for medullary thyroid cancer in Europe

2024 · Grace Segall, Ravinder Singh, et al. · European Thyroid Journal · 4

Real-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RET

2026 · J. Hadoux, J. Hernando, et al. · ESMO Open · 2

Characteristics, treatment patterns, and biomarker testing of patients with advanced RET fusion-positive non-small cell lung cancer in a real-world multi-country observational study: a brief report

2025 · Urpo Kiiskinen, Grace Segall, et al. · Frontiers in Oncology · 2

270TiP Olomorasib and immunotherapy in stage II-III KRAS G12C-mutant NSCLC after definitive therapy: SUNRAY-02 study rationale

2026 · J. Chaft, M.C. Garassino, et al. · ESMO Open · 1

Real-World Clinical Profile, Treatment Patterns And Patient-Reported Outcomes for Thyroid Cancer in Japan

2023 · Naoki Fukuda, Yoshinori Tanizawa, et al. · Future Oncology · 1

SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy

2026 · Jamie Chaft, Jay M. Lee, et al. · Future Oncology

Treatment patterns and outcomes for patients with RET-altered thyroid cancer treated with selpercatinib in europe: final results from the sprint-RET study

2026 · Wong Kee Howe, Christine Spitzweg, et al. · Endocrine Abstracts

Outcomes of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer Treated with First-Line Non-Molecularly Targeted Therapies: A Real-World Benchmark in Europe from the RECALIB-RET Study

2026 · Luis León-Mateos, Maximillian J. Hochmair, et al. · Advances in Therapy

61P Treatment patterns and outcomes of patients with RET fusion-positive non-small cell lung cancer (NSCLC) treated with selpercatinib in Europe: Final results from the SPRINT-RET study

2026 · M.J. Hochmair, G. Lo Russo, et al. · ESMO Open

Disease management landscape in patients with mantle cell lymphoma in Japan: a real-world study

2025 · Shinya Rai, Yoshinori Tanizawa, et al. · Future Oncology

Works count: 16

Citation count: 20

H-index: 3

I10-index: